CRL Stock Forecast & Price Target

Charles River is viewed positively because its core preclinical and development franchises are showing improving demand, highlighted by a solid Q3 beat and raise and a 5th consecutive quarter of strengthening leading indicators in DSA and Manufacturing. The outlook is further supported by conservative long-term growth assumptions of 5%-7% organic revenue growth, expanding margins, and segment-specific upside from pricing, automation, bioanalysis expansion, and a shift toward higher-margin post-IND work. Management’s large NAMs platform, with 220+ capabilities, and the durability of its Manufacturing mix and recurring consumables suggest the company is not being disrupted by AI and alternative methods so much as positioned to benefit from their gradual integration.

Charles River is facing a bearish setup because its growth thesis depends on a 2H26/2027 demand inflection that could fail if biopharma funding does not convert into more preclinical study starts. The downside case already assumes LSD growth and 200bps margin compression in 2027, while the model also relies on K.F. (Cambodia) delivering $16M in 2026 and $39M in 2027 EPS accretion plus 120bps of operating margin uplift, both of which could be undermined by integration or supply-chain issues. Longer term, limited NAMs exposure of about $120M revenue and minimal safety penetration leaves its roughly 70% DSA segment vulnerable to structural erosion if FDA acceptance of organ-on-chip, organoid, and in silico methods advances faster than expected.